Dyadic International announced its 2025 financial results, reporting a net loss of $7.36 million and total revenue of $3.09 million. The company highlighted significant progress including the commercial launch of AlbuFree™ DX recombinant human albumin, expanded collaborations with Fermbox Bio, and new OEM distribution agreements. Dyadic is advancing its portfolio of animal-free proteins and enzymes across life sciences, food, nutrition, and bio-industrial sectors, aiming to increase recurring revenue streams. The company also noted ongoing development in vaccine and antibody production platforms, supported by grants from the Gates Foundation and CEPI, and plans to expand commercial efforts in Asia.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
